AHCO vs HCSG

For growth investors, Healthcare Services Group, Inc.

(HCSG) is the stronger pick with 7. 1% revenue growth year-over-year, versus -0. 5% for AdaptHealth Corp. (AHCO). Healthcare Services Group, Inc. (HCSG) offers the better valuation at 27. 2x trailing P/E (20. 6x forward), making it the more compelling value choice. Analysts rate AdaptHealth Corp. (AHCO) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, AdaptHealth Corp.

is actually cheaper at 11. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Healthcare Services Group, Inc.

(HCSG) delivered a total return of -21. 4%, compared to -55. 1% for AdaptHealth Corp. (AHCO). Over 10 years, the gap is even starker: AHCO returned +17. 6% versus HCSG's -27. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AdaptHealth Corp.

(AHCO) is the lower-risk stock at 0. 83β versus Healthcare Services Group, Inc. 's 1. 12β — meaning HCSG is approximately 36% more volatile than AHCO relative to the S&P 500. On balance sheet safety, Healthcare Services Group, Inc. (HCSG) carries a lower debt/equity ratio of 5% versus 125% for AdaptHealth Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Healthcare Services Group, Inc.

(HCSG) is pulling ahead at 7. 1% versus -0. 5% for AdaptHealth Corp. (AHCO). On earnings-per-share growth, the picture is similar: Healthcare Services Group, Inc. grew EPS 52. 8% year-over-year, compared to -185. 2% for AdaptHealth Corp.. Over a 3-year CAGR, AHCO leads at 3. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Healthcare Services Group, Inc.

(HCSG) is the more profitable company, earning 3. 2% net margin versus -2. 2% for AdaptHealth Corp. — meaning it keeps 3. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AHCO leads at 5. 7% versus 2. 6% for HCSG. At the gross margin level — before operating expenses — AHCO leads at 17. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AdaptHealth Corp.

(AHCO) trades at 11. 4x forward P/E versus 20. 6x for Healthcare Services Group, Inc. — 9. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HCSG: 11. 0% to $24. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, AdaptHealth Corp.

(AHCO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 83)). Both have compounded well over 10 years (AHCO: +17. 6%, HCSG: -27. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.